Longeveron Inc. (LGVN)
| Market Cap | 5.58M -71.1% |
| Revenue (ttm) | 1.19M -42.7% |
| Net Income | -23.47M |
| EPS | -9.73 |
| Shares Out | 3.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 64,775 |
| Open | 1.750 |
| Previous Close | 1.780 |
| Day's Range | 1.731 - 1.830 |
| 52-Week Range | 1.310 - 12.300 |
| Beta | -0.20 |
| Analysts | Buy |
| Price Target | 61.25 (+3,400.0%) |
| Est. Earnings | Nov 10, 2026 |
About LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated... [Read more]
Financial Performance
In 2025, Longeveron's revenue was $1.20 million, a decrease of -49.87% compared to the previous year's $2.39 million. Losses were -$22.70 million, -7.79% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for LGVN stock is "Buy." The 12-month stock price target is $61.25, which is an increase of 3,400.00% from the latest price.
News
Longeveron Announces Engagement of Lucid Capital Markets
MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (the “Company”) (NASDAQ: LGVN), today announced that the Company has retained Lucid Capital Markets, LLC as the Company's financial advisor to ...
Longeveron reports ELPIS II trial misses primary endpoint
Longeveron (LGVN) announced updated results from ELPIS II following planned additional analysis conducted by the company and the National Institutes of Health, or NIH, funded trial investigators. ELPI...
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
ELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association's (AHA) 2026 Scientific Sessions As previously reported, the ELPIS II trial did...
Longeveron to Participate in Three Longevity/Aging Investment Conferences
MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic ag...
Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial
Longeveron stock took a 56.14% beating on Thursday after the company posted a failed clinical trial.
Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition
Longeveron on Wednesday said it would explore strategic options after its experimental stem cell therapy failed to meet the main goal of a mid-stage trial for a rare infant heart condition.
Longeveron down 55% at $2.98 after resumption of trade
Shares of Longeveron (LGVN) are down 55% after the resumption of trade after the company announced that laromestrocel did not meet primary endpoint in Phase 2b HLHS trial. Published first…
Longeveron to resume trading at 5:55 pm ET
Longeveron (LGVN) is scheduled to resume quoting at 5:50 pm ET and to resume trading at 5:55 pm ET, according to Nasdaq. Shares were halted, pending news, ahead of the…
Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial
Longeveron (LGVN) announced topline results from ELPIS II, its Phase 2b clinical trial evaluating its investigational stem cell therapy laromestrocel as an adjunct to Stage 2 palliative surgery in 40…
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Company Announces Exploration of All Options to Maximize Shareholder Value The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular eje...
Longeveron Inc trading halted, news pending
16:55 EDT Longeveron (LGVN) Inc trading halted, news pending
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Longeveron to present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026; presentation 9/14/26 at 1:00pm ET
Longeveron Inc trading halted, news pending
19:50 EDT Longeveron (LGVN) Inc trading halted, news pending
Longeveron announces 1-for-10 reverse stock split
Longeveron (LGVN) announced that the company will undertake a 1-for-10 reverse split of the company’s Class A common stock, par value $0.001 per share and Class B common stock, par…
Longeveron Announces 1-for-10 Reverse Stock Split
MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relat...
Longeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed
Longeveron (LGVN) announced that the company has appointed Nirav Jhaveri to the company’s executive leadership team in the role of CFO, principal financial officer and principal accounting officer. He...
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 ...
Longeveron reports Q2 EPS (19c) vs. (33c) last year
Reports Q2 revenue $287,000 vs. $316,000 last year. “Longeveron (LGVN) is approaching a series of potentially transformative milestones across our four stem cell therapy development programs that have...
Longeveron Earnings Call Transcript: Q2 2026
Q2 2026 saw a 10% revenue decline and a net loss increase to $6.1 million, with cash runway into Q4 2026. Key milestones include the upcoming ELPIS II data readout for HLHS and recognition as an XPRIZE Healthspan finalist, supporting partnership and regulatory strategies.
Longeveron Quarterly report: Q2 2026
Longeveron has published its Q2 2026 quarterly earnings report on August 12, 2026.
Longeveron Earnings release: Q2 2026
Longeveron released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediat...
Longeveron Slides: Investor presentation
Longeveron has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
Longeveron selected as a Milestone 2 Awardee based on published clinical trial results which demonstrated laromestrocel increased 6-minute walk distance in patients with Aging-related Frailty MIAMI, A...